SK bioscience Co., Ltd.

ACTIVE

310 Pangyo-ro, Bundang-gu, 京畿道城南市, 京畿道, South Koreawww.skbioscience.co.krPublic1,095 employeesEstablished: 2018-07-02

Part of SK Chemicals Co. Ltd.

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2018

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

50.0%

Phase 3

41.7%

Trial Status Distribution

Active, not recruiting

8.3%

Completed

66.7%

Recruiting

8.3%

Unknown

8.3%

Withdrawn

8.3%

Clinical Trials

Trials sponsored by this organization (12)

SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years

Phase 3

Recruiting

interventional

Jul 2026780 participants

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.

Phase 1

Active, not recruiting

interventional

Jan 2026368 participants

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Phase 1

Completed

interventional

Feb 2025161 participants

A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.

Withdrawn

observational

Feb 2023

Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older

Phase 3

Completed

interventional

Dec 2022840 participants

Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)

Phase 3

Completed

interventional

Aug 20214,036 participants

Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)

Phase 1

Unknown

interventional

Feb 2021328 participants

Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)

Phase 1

Completed

interventional

Jan 2021260 participants

Page 1 of 2

Approvals

Approvals by Agency

NPRA

National Pharmaceutical Regulatory Agency

Approvals

Recent Approvals

SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.25ml

NPRA

2025-11-28

SKYCellflu Quadrivalent Prefilled Syringe 0.5ml

NPRA

2025-11-28

SKYZoster powder and solvent for suspension for injection

NPRA

2025-11-28

SKYVaricella powder and solvent for suspension for injection

NPRA

2025-11-28

SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.5ml

NPRA

2025-07-07

News

No news articles found

Back to Organizations